LipoScience to Market LipoProfile Test

Under the terms of an agreement with Laboratory Corporation of America (Burlington, NC, USA), LipoScience, Inc. (Raleigh, NC, USA), will offer LabCorp.'s nuclear magnetic resonance (NMR) LipoProfile test to its customers through its sales and distribution network.

The NMR LipoProfile is a blood test that has been shown in numerous clinical studies to be superior to low-density lipoprotein (LDL) cholesterol in predicting coronary artery disease. Unlike traditional cholesterol tests, the NMR test uses NMR spectroscopy to measure the actual number of atherogenic LDL particles that build up in the arteries and cause heart disease. Doctors have traditionally estimated the number of such particles by measuring the LDL cholesterol they contain.

Patients with a high number of LDL particles are at increased risk for heart disease, even if they have normal cholesterol levels. By knowing how many of these particles are circulating in the blood, a doctor can get a more accurate picture of a patient's heart health and make better patient-care decisions.

"Entering into this agreement with LabCorp accelerates our strategy of making our technology available for broad use in clinical laboratories worldwide,” observed Richard O. Brajer, president and CEO, LipoScience. "Clinicians increasingly understand the need to go beyond cholesterol measurement in assessing the risk for heart disease and monitoring response to therapy. This relationship with LabCorp will help address that need.”





Related Links:
LipoScience
LabCorp